Gildemann Kiira, Tsernant Mari-Liis, Liivand Laura, Ennomäe Retti, Poikalainen Väino, Lepasalu Lembit, Rom Siimu, Kavak Ants, Cox Robert Marsden, Wolf Josef Dieter, Lieber Carolin Maria, Plemper Richard Karl, Männik Andres, Ustav Mart, Ustav Mart, Gerhold Joachim Matthias
Icosagen Cell Factory OÜ, Õssu, Kambja vald, 61713 Tartumaa, Estonia.
Teadus ja Tegu OÜ, Märja, 61406 Tartu, Tartumaa, Estonia.
iScience. 2024 Jun 20;27(7):110326. doi: 10.1016/j.isci.2024.110326. eCollection 2024 Jul 19.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread in the population. We recently reported the production of bovine colostrum-derived antibodies that can neutralize the virus. These have been formulated into a nasal spray. The immunoglobulin preparation is capable of blocking interaction of the trimeric spike protein (Tri S) of SARS-CoV-2 with the cellular receptor angiotensin-converting enzyme 2 (ACE2), entry of a pseudovirus carrying the Tri S into ACE2 over-expressing human embryonic kidney (HEK) cells, and entry of the virus into live Vero E6 cells. Using an ELISA assay, we demonstrate here that this holds true for different SARS-CoV-2 variants of concern. Using the ferret transmission model, we show that the nasal spray formulation of anti-SARS-CoV-2 immunoglobulins efficiently blocks transmission of SARS-CoV-2 from infected to uninfected ferrets. The results indicate that the use of the nasal spray in humans can add an effective additional layer of protection against the virus, and might be applicable for other viruses of the upper respiratory tract.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）仍在人群中传播。我们最近报道了能够中和该病毒的牛初乳衍生抗体的产生。这些抗体已被制成鼻喷雾剂。该免疫球蛋白制剂能够阻断SARS-CoV-2三聚体刺突蛋白（Tri S）与细胞受体血管紧张素转换酶2（ACE2）的相互作用、携带Tri S的假病毒进入过表达ACE2的人胚肾（HEK）细胞以及病毒进入活的Vero E6细胞。在此，我们通过酶联免疫吸附测定（ELISA）证明，这对于不同的SARS-CoV-2变异株同样适用。利用雪貂传播模型，我们表明抗SARS-CoV-2免疫球蛋白的鼻喷雾剂制剂能有效阻断SARS-CoV-2从感染雪貂向未感染雪貂的传播。结果表明，在人类中使用鼻喷雾剂可以增加一层有效的针对该病毒的额外保护，并且可能适用于其他上呼吸道病毒。
